Singular Genomics Systems, Inc. (OMIC)
NASDAQ: OMIC · IEX Real-Time Price · USD
0.415
+0.014 (3.62%)
Apr 23, 2024, 2:29 PM EDT - Market open
Company Description
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine.
The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets.
Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.
Singular Genomics Systems, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 27, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 255 |
| CEO | Andrew Spaventa |
Contact Details
Address: 3010 Science Park Road San Diego, California 92121 United States | |
| Phone | (858) 333-7830 |
| Website | singulargenomics.com |
Stock Details
| Ticker Symbol | OMIC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001850906 |
| CUSIP Number | 82933R100 |
| ISIN Number | US82933R1005 |
| Employer ID | 81-2948451 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Andrew Spaventa | Founder, Chief Executive Officer, President and Chairperson of the Board |
| Dr. David L. Barker Ph.D. | Founder, Member of Scientific Advisory Board and Independent Director |
| Dr. Eli N. Glezer Ph.D. | Founder, Chief Scientific Officer and Chair of Scientific Advisory Board |
| Dalen Meeter | Chief Financial Officer |
| Jyotsna Ghai | Chief Operating Officer |
| Jeff Bullard | Head of Sales |
| Vincent Brancaccio | Head of Human Resources |
| Jorge Velarde Jr., MBA | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 18, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 18, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |